Nymox Pharmaceutical: Employee Resume Substantiates Concerns

Nymox Pharmaceutical: Employee Resume Substantiates Concerns Despite repeatedly telling investors that it would file for approval, Nymox has never filed a marketing application in the US and withdrew the application it filed in Europe.Nymox has most recently claimed it would file for approval in 1H20 but we are skeptical.Resume of former employee validates concerns: we believe NYMX was never close to filing an NDA or an adequate MAA, and will likely be unable to file anytime soon. Nymox Corp (NASDAQ: NYMX) has been developing NX-1207 for the treatment of benign prostatic hyperplasia (BPH) for the last 20 years. In 2014, two pivotal Phase III trials missed their primary endpoint. Instead of conducting another set of trials in consultation with the FDA and EMA, Nymox has pursued tangents for the last 5 years – reporting data from long-term extension studies (extremely unlikely to be accepted by FDA as adequate evidence of efficacy), and claiming that approval filings would be made i...